Amwell (AMWL) Q4 2025 earnings review
Shrinking to Survive: Revenue Collapse Overshadows Efficiency
Amwell has entered a dramatic contraction phase. While Q4 revenue of $55.3M beat guidance, the forward outlook is alarming: FY26 revenue guidance of $195-$205M implies a ~20% decline from FY25 levels. Management is aggressively cutting costs to achieve cash flow breakeven by Q4 2026, successfully narrowing Adjusted EBITDA losses. However, with cash reserves down to $182M and the core business shrinking, the company is racing to cut expenses faster than revenue falls.
🐂 Bull Case
Cost discipline is working. Adjusted EBITDA loss narrowed to $10.3M in Q4, and FY26 guidance suggests losses will shrink further to ~$21M for the full year. The burn rate is decelerating significantly.
The Military Health System deployment remains a sticky, high-margin anchor. Despite Q2's one-time lumpiness, this government contract provides a baseline of recurring software revenue that competitors lack.
🐻 Bear Case
FY26 revenue guidance ($195-205M) represents a steep contraction from FY25 ($249M). Even accounting for divestitures, the core business is shrinking, with Q1 26 guidance ($48-53M) hitting a new low.
Cash balance fell from $228M to $182M YoY. While the burn is slowing, they are spending reserves to manage a shrinking business. If they miss the Q4 2026 breakeven target, liquidity becomes a crisis.
⚖️ Verdict: 🔴
Bearish. The 'path to profitability' is being achieved through massive shrinkage rather than operating leverage. A software company guiding for a ~20% revenue decline while still burning cash is a difficult investment case.
Key Themes
Revenue Guidance Cliff
Reversing. The FY26 revenue outlook is a major red flag. Management guides $195-$205M, significantly below the $249M achieved in FY25. The Q1 2026 guide of $48-$53M indicates the contraction is immediate, driven by divestitures and lower visit volumes. The growth story has effectively halted.
Visit Volume Erosion
Decelerating. Total visits fell to 1.0 million in Q4 2025 from 1.1 million in Q3 and 1.4 million a year ago. As Amwell pivots to a SaaS model, they are shedding visit revenue, but the decline in volume suggests lower utilization of the platform by the remaining install base.
Operational Efficiency
Accelerating. This is the company's strongest metric. Adjusted EBITDA improved from ($22.8M) in 24Q4 to ($10.3M) in 25Q4. Management is successfully cutting R&D and S&M expenses faster than revenue is falling, which is the only path to the promised 2026 breakeven.
Strategic Divestitures
Amwell is selling off parts of itself to survive. The guidance specifically notes the divestiture of Amwell Psychiatric Care. While this improves margins (gross margin held at 51% in Q4), it significantly contributes to the topline revenue drop. The company is becoming smaller but more focused on technology.
Defense Health Agency (DHA) Stability
The DHA contract remains a critical driver. While the large one-time revenue recognition in Q2 2025 created a difficult comp for subsequent quarters, this relationship provides the 'SaaS backbone' that prevents a complete revenue freefall.
Other KPIs
Down from $228.3M a year ago. The burn rate has slowed, but the company must bridge the gap to Q4 2026 breakeven without raising capital in a difficult environment.
Stable/Growing mix. Subscription revenue is now the core focus as visit revenue declines. It represents 53% of total FY25 revenue, up from ~45% in FY24.
Improving. Loss nearly halved compared to 24Q4 ($44.6M). The heavy lifting on restructuring charges appears to be largely complete.
Guidance
Reversing. Represents a ~20% YoY decline from FY25's $249M. Management attributes this to divestitures and a focus on 'revenue quality,' but it is a sharp contraction.
Accelerating improvement. A massive improvement from FY25's ($39.9M) loss. Implies quarterly losses will average ~$5M, putting the Q4 breakeven goal within reach if revenue doesn't miss.
Decelerating. Down from $55.3M in Q4 25 and $66.8M in Q1 25. The business is resetting to a significantly smaller baseline.
Stable/Improving. Continues the trend of single-digit million quarterly losses, consistent with the annual profitability target.
Key Questions
Revenue Floor
With FY26 guidance down ~20%, where is the organic floor for the business? How much of this decline is divestitures vs. organic churn?
Breakeven Viability
The plan for Q4 2026 cash flow breakeven seems entirely dependent on cost cutting. If revenue slips below the $195M low end, do you have room to cut costs further without damaging the platform?
Cash Buffer
With $182M in cash and continued burn through 2026, what is the minimum cash operating level required before you need to consider financing?